BUZZ-Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug

** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at A$4.135, set for a fourth consecutive session of gain

** Radiopharma co says the U.S. Food and Drug Administration has granted Fast Track Designation for its prostate cancer drug, 64Cu-SAR-bisPSMA

** Says the drug has several advantages over currently approved ones, including improved diagnostic performance and flexible imaging schedule, among others

** Stock rises as much as 15.5% earlier in the day, marking its biggest intraday pct gain since Dec. 18, 2024

** About 2 mln shares change hands, 1.1x the 30-avg

** Stock more than doubled in value last year